Document:

Exhibit 10.7

                                LICENSE AGREEMENT

      THIS LICENSE AGREEMENT (the "Agreement"), dated as of April 26th, 2001, by
and between  JOSE  ANTONIO  O'DALY  ("OWNER")  and  ASTRALIS,  LLC, a New Jersey
limited liability company ("LICENSEE").

                                    RECITALS

      WHEREAS, OWNER is the owner of United States patent application Serial No.
09-809003,  filed  March 16,  2001  entitled  "Compositions  and Methods for the
Treatment and Clinical Remission of Psoriasis" (the "Invention").

      WHEREAS,  LICENSEE  desires  to obtain  an  exclusive  license  to use and
exploit the Invention and the technology related thereto,  including the ability
to license  foreign  patent  rights,  and OWNER desires to grant such  exclusive
license, upon the terms and conditions set forth in this Agreement;

      NOW, THEREFORE,  in consideration of the foregoing recitals and the mutual
covenants and agreements of the parties contained in this Agreement, the parties
hereby agree as follows:

1.    DEFINITIONS.

      For the purposes of this  Agreement,  the  following  terms shall have the
meanings set forth in this Section 1:

      1.1  "Combination  Product(s)"  shall mean any product  containing  both a
pharmaceutically active agent or ingredient which constitutes a Licensed Product
and one or more other pharmaceutically active agents or ingredients which do not
constitute Licensed Products.

      1.2  "Confidential  Information"  shall mean all  tangible  or  intangible
information,  whether oral, written or in any other medium, directly relating to
the Invention.  "Confidential  Information" shall include, by way of example but
not limitation,  the Invention and any derivations  thereof,  all trade secrets,
copyrightable  works,   patentable  works,   know-how,   designs,   innovations,
discoveries,  formulations,  specifications,  improvements,  processes, response
rates, product data, supplier lists,  customer lists, price lists,  purchase and
sales  records,  other  sales  information  financial   information,   marketing
information,   computer   programs,   manuals  or  documentation  of  any  kind.
"Confidential  Information"  shall not include  information  which is or becomes
generally available to the public (other than as a result of a disclosure by the
LICENSEE or any Sublicensee or their representatives).

      1.3 "Licensed  Product(s)"  shall mean tangible  materials  which,  in the
course of  manufacture,  use, or sale would,  in the absence of this  Agreement,
infringe upon one or more claims of the Patent Rights.

                                       1
<PAGE>

      1.4 "Patent Rights" shall mean the U.S.  patents and patent  applications,
and any non-U.S.  patent  applications for the Invention,  including any and all
and division(s),  continuation(s) or  continuation-in-part(s)  thereof, together
with the equivalent thereof issuing thereon or any reissue or extension thereof.

      1.5 "Sublicensee"  shall mean any third party to whom LICENSEE has granted
a license to make, have made, use and/or sell the Licensed Product(s).

2.    GRANT OF  EXCLUSIVE  RIGHT TO  LICENSEE TO DEVELOP  AND  SUBLICENSE  FOR A
      LIMITED PERIOD OF TIME.

      2.1 OWNER hereby grants to LICENSEE the exclusive right and license to use
and exploit the Invention and the Patent  Rights and, to make,  have made,  use,
sell and import Licensed  Product(s) and/or Combination  Products throughout the
world during the term of this Agreement.

      2.2  OWNER  shall  retain  the  right  to  Manufacture  and  use  Licensed
Product(s)  in its own  laboratories  or in the  laboratories  of third  parties
exclusively for scientific purposes and for continued research.

      2.3 Subject to the  provisions  of Section  2.4,  LICENSEE  shall have the
right to grant a sublicense  with  respect to the rights and license  granted to
LICENSEE under this Agreement.

      2.4 Unless the parties  otherwise  agree, the right of LICENSEE to grant a
sublicense is subject to the fulfillment of the following terms and conditions:

            (a) Any sublicense  must be in writing and must  explicitly  provide
that the Sublicensee shall have, at a minimum,  the same obligations to OWNER as
the obligations of LICENSEE under this Agreement.

            (b)  LICENSEE  shall not grant to any  third-party  any right to the
Invention  which  extends  beyond  the  termination  of the  license  under this
Agreement.

3.    ROYALTIES.

      3.1 For the rights and license  granted  hereunder,  LICENSEE shall pay to
OWNER a royalty  payment of Ten Dollars  ($10.00) within ten (10) days after the
execution of this License Agreement.

4.    PATENT PROSECUTION AND MAINTENANCE.

      4.1  During  the  term  of  this  Agreement,   OWNER  shall  have  primary
responsibility for the prosecution, filing and maintenance of all Patent Rights;
PROVIDED,  HOWEVER, LICENSEE shall have a reasonable opportunity to consult with
OWNER   regarding  such  matters,

                                       2
<PAGE>

and shall  cooperate  with OWNER in such  prosecution,  filing and  maintenance.
OWNER will be obligated to pursue the patent in good faith.

      4.2 During  the term of this  Agreement,  LICENSEE  shall pay all fees and
costs relating to the filing, prosecution, and maintenance of the Patent Rights.
OWNER is not financially obliged to maintain and prosecute patents or any Patent
Rights during the term of this Agreement.

      4.3  LICENSEE  shall  cause each of its  employees  and agents to take all
actions and to execute,  acknowledge  and deliver all  instruments or agreements
reasonably  requested by OWNER for the perfection,  maintenance,  enforcement or
defense of OWNER's rights to or in the Invention and the Patent Rights.

5.    INFRINGEMENT.

      5.1 LICENSEE and OWNER shall each inform the other  promptly in writing if
either of them become aware of any alleged  infringement  of Patent  Rights by a
third party.

      5.2 OWNER shall have the right, in his  discretion,  to elect to prosecute
any claims arising from the infringement of the Patent Rights. In the event that
OWNER  chooses not to prosecute  any claim for  infringement  within thirty (30)
days of when he becomes  aware of such  infringement,  or if the OWNER  fails to
diligently  pursue any  infringement  action,  LICENSEE  shall have the right to
pursue the infringement action. In such event, LICENSEE shall have the right, if
OWNER is a legally indispensable party, to bring such suit or action in the name
of OWNER.  OWNER shall have the right to join any such suit or action brought by
LICENSEE.

      5.3  LICENSEE  shall pay all  reasonable  attorneys'  fees and other costs
incurred by OWNER or LICENSEE in an  infringement  action,  including any action
described in Section 5.6.

      5.4  LICENSEE  shall be entitled to retain all amounts  received by either
OWNER or LICENSEE from any  infringement  action if this  Agreement has not been
terminated.

      5.5  LICENSEE  shall not enter into any  settlement,  consent  judgment or
other voluntary final  disposition of any infringement  action without the prior
written consent of OWNER,  which consent shall not be  unreasonably  withheld or
delayed.

      5.6 In the  event  that  any  person  commences  an  action  alleging  the
invalidity or  non-infringement  of any of the Patent Rights  against  LICENSEE,
LICENSEE shall promptly notify OWNER,  and the parties shall consult  concerning
the action to be taken. OWNER, at its option, shall have the right within thirty
(30) days after  commencement of such action to intervene and assume the defense
of the action, with counsel selected by OWNER.  LICENSEE shall have the right to
join in the defense of any such suit or action by OWNER.  In such  event,  OWNER
will confer with LICENSEE prior to making any decision  regarding  settlement or
other  significant  decisions  regarding the action and no such decision will be
made without LICENSEE's consent, which consent will not be unreasonably withheld
or delayed.

                                       3
<PAGE>

6.    COMMERCIALIZATION AND FOOD AND DRUG ADMINISTRATION APPROVAL.

      6.1  LICENSEE  shall use its best  efforts,  either  directly or through a
Sublicensee, to bring one or more Licensed Products to market through a vigorous
and diligent  program for  exploitation  of the Patent Rights to attain  maximum
commercialization of Licensed Products.

      6.2  LICENSEE  shall use its best  efforts,  either  directly or through a
Sublicensee,  to obtain approval of the US Food and Drug  Administration for the
commercial sale of Licensed Products in the United States of America.

7.    REPRESENTATIONS AND WARRANTIES.

      7.1 OWNER represents and warrants to LICENSEE that:

      (a) This Agreement  constitutes the legal, valid and binding obligation of
OWNER, enforceable against the OWNER in accordance with its terms.

      (b) No  authorization  or approval or other action by, and no notice to or
filing with, any governmental authority or regulatory bodies is required for the
due execution, delivery and performance of this Agreement by the OWNER.

      (c) To OWNER's knowledge,  OWNER has the sole,  exclusive and unencumbered
right to grant the licenses and rights granted to LICENSEE under this Agreement.

      (d) OWNER has not granted any option,  license, right or interest in or to
the Invention to any third party which would conflict with the rights granted by
this Agreement.

      7.2 LICENSEE represents and warrants to OWNER that:

      (a) LICENSEE has duly authorized the execution,  delivery and performanTce
of this Agreement and this Agreement  constitutes  the legal,  valid and binding
obligation of the LICENSEE,  enforceable against the LICENSEE in accordance with
its terms.

      (b) No  authorization  or approval or other action by, and no notice to or
filing with, any governmental authority or regulatory bodies is required for the
due execution, delivery and performance of this Agreement by the LICENSEE.

8.    TERM; TERMINATION.

      8.1  This  Agreement  shall  have a term  commencing  on the  date of this
Agreement and expiring on the last date of expiration of any patent  included in
the Patent Rights,  unless  terminated on an earlier date in accordance with the
provisions of this Section 8.

                                       4
<PAGE>

      8.2 The  occurrence of any of the following  shall  constitute an event of
default under this Agreement (an "Event of Default"):

            (a)  The  institution  of  any  bankruptcy,  insolvency  or  similar
proceeding by or against  LICENSEE in any  jurisdiction,  the  appointment  of a
receiver  for  LICENSEE's  business  or a  substantial  part of its assets or an
assignment for the benefit of LICENSEE's creditors.

            (b) The dissolution or liquidation of LICENSEE.

      8.3 Upon the occurrence of any Event of Default listed in Section  8.2(a),
(b) or (c),  OWNER shall have the right to terminate  this Agreement upon giving
written  notice to the LICENSEE  thirty (30) days prior to the effective date of
termination,  and if the cause for such notice is not cured  within such period,
then at the  expiration of such thirty (30) day period,  this  Agreement and all
rights  and  licenses  granted to the  LICENSEE  hereunder  shall  automatically
terminate. Upon the occurrence of any Event of Default listed in Section 8.2(a),
OWNER shall have the right to terminate this Agreement upon notice to LICENSEE.

      8.4 In the event of termination  of the license  rights granted  hereunder
for any reason(s) whatsoever:

            (a) The  obligations  of the parties under Section 9 shall remain in
full force and effect;

            (b) The OWNER agrees to negotiate  with  sublicensee  in good faith;
and

            (c) LICENSEE shall return,  deliver, and assign to OWNER all records
regardless of medium containing any Confidential Information,  together with all
other  documents  which relate to or describe the  manufacture,  use,  sale,  or
characteristics  of the Invention and/or Licensed  Products and or Patent Rights
which are in its possession, custody, or control.

      8.6 The  termination of this  Agreement  shall not affect or prejudice any
other  provisions  of this  Agreement  which  are  expressly  or by  implication
provided to continue in effect after such termination.

9.    NONDISCLOSURE OF CONFIDENTIAL INFORMATION.

      9.1 Neither  party  shall use any  Confidential  Information  of the other
party for any purpose except to exercise its rights and perform its  obligations
under this Agreement.  Neither party shall disclose any Confidential Information
of the other  party to third  parties or to such  party's  employees,  except to
those employees of the receiving party with a need to know.  Notwithstanding the
above,  either  party may  disclose  information  on a  "need-to-know"  basis to
potential  business  associates with the approval of the other party, which will
not be unreasonably withheld or delayed.

                                       5
<PAGE>

      9.2 Each party  shall take  reasonable  measures to protect the secrecy of
and avoid disclosure and unauthorized use of the Confidential Information of the
other  party.  Without  limiting the  foregoing,  each party shall take at least
those  measures  that it  takes to  protect  its own  most  highly  confidential
information, and shall ensure that its employees who have access to Confidential
Information of the other party a non-use and non-disclosure agreement in content
similar  to the  provisions  hereof  prior  to any  disclosure  of  Confidential
Information  to such  employees.  Neither  party  shall  make any  copies of the
Confidential  Information  of the other party  under the other party  previously
approves  the same in writing.  Each party  shall  reproduce  the other  party's
proprietary  rights notices on any such approved  copies,  in the same manner in
which such notices were set forth in or on the original.

10.   DISPUTE RESOLUTION.

      10.1 The  parties  hereby  agree  that they will  attempt in good faith to
resolve any  controversy  or claim arising out of or relating to this  Agreement
promptly by negotiation.  If a controversy or claim should arise hereunder,  the
representatives  of the parties will meet in Morris County, New Jersey,  within
thirty  (30)  days,  to confer at least once and will  attempt  to  resolve  the
matter.  If the matter has not been resolved  within fourteen (14) days of their
first meeting,  the representatives  shall have the right to refer the matter to
arbitration,  subject to rights to injunctive  relief and specific  performance,
and unless otherwise  specifically provided for herein, any controversy or claim
arising out of or relating to this  Agreement,  or the breach  thereof,  will be
settled as set forth in Section 10.2.

      10.2.  Except as provided in Section 10.3, all disputes,  controversies or
differences  which may arise  between  the parties out of or in relation to this
Agreement  or any default or breach  thereof may be resolved by  arbitration  in
accordance with the then-current  rules of American  Arbitration  Association by
one or more arbitrators appointed in accordance with such rules. Any arbitration
shall take place in Morris County,  New Jersey.  Any decision or award resulting
from the  arbitration  provided  for in this  Section  10.2  shall be final  and
binding on the parties.

      10.3  Notwithstanding  Section  10.3,  either party has the right to bring
suit in a court of competent jurisdiction against the other party for any breach
of such other party's  duties of  confidentiality  pursuant to Section 9 of this
Agreement.  Judgment upon the arbitrator's  award may be entered in any court of
competent jurisdiction.

11.   MISCELLANEOUS.

      11.1 Entire Agreement; Modifications. Except as otherwise provided in that
certain  Operating  Agreement of Astralis,  LLC dated ____, 2001, this Agreement
constitutes the parties' entire  agreement with respect to the subject matter of
this  Agreement and  supersedes  all  agreements,  representations,  warranties,
statements,  promises and understandings,  whether oral or written, with respect
to the subject  matter of this  Agreement.  This  Agreement  may not be amended,
altered or modified except by a writing signed by both of the parties.

                                       6
<PAGE>

      11.2 Waivers Strictly Construed. With regard to any power, remedy or right
provided  in this  Agreement  or  otherwise  available  to any party  under this
Agreement;  (i) no  waiver  or  extension  of time  shall  be  effective  unless
expressly  set  forth in a  writing  signed by the  waiving  party;  and (ii) no
alteration, modification or impairment shall be presumed to be given to LICENSEE
by reason of any  previous  waiver,  extension  of time,  delay or  omission  in
exercise, or other indulgence.

      11.3  Successors And Assigns.  Except as provided  herein to the contrary,
this Agreement  shall inure to the benefit of and be binding upon the parties to
this Agreement and their respective successors and permitted assigns.  Except as
otherwise  provided in Section 2 hereof;  PROVIDED,  HOWEVER,  that LICENSEE may
assign  its  rights  under  this   Agreement  in   connection   with  a  merger,
consolidation  or sale of  substantially  all of the assets of  LICENSEE  if the
successor  entity agrees in writing  prior to the  assignment to be bound by all
the terms and conditions of this Agreement. Any attempt by LICENSEE to assign or
delegate  any portion of this  Agreement  in  violation  of this  Section 11 and
Section 2 shall be null and void.

      11.4 Notices. All notices under this Agreement will be in writing and will
be  delivered  by  personal  service or  facsimile  or  certified  mail (or,  if
certified mail is not available,  then by first class mail), postage prepaid, to
such address as may be designated from time to time by the relevant  party,  and
which will  initially  be as set forth in Section  11.4(b).  Any notice  sent by
certified  mail will be deemed to have been given  three (3) days after the date
on which it is mailed. All other notices will be deemed given when received.  No
objection may be made to the manner of delivery of any notice actually  received
in writing by an  authorized  agent of a party.  Notices  will be  addressed  as
follows or to such other  address as the party to whom the same is directed will
have specified in conformity with the foregoing:

                  If to LICENSEE:            ASTRALIS, LLC
                                             135 Columbia Turnpike, Suite 301
                                             Florham Park, New Jersey 07932
                                             Attn:    Mike Ajnsztajn

                  If to OWNER:               Jose Antonio O'Daly
                                             Terraza D Club Hipico
                                             Calle Colombia
                                             Quinta SUNSET
                                             Caracas, Venezuela

      11.5  Governing Law;  Consent To  Jurisdiction.  This  Agreement  shall be
governed by, and  construed  and enforced in  accordance  with,  the laws of the
State of New Jersey without regard to the conflict of laws rules of the State of
New Jersey or any other  jurisdiction that would call for the application of the
laws of any jurisdiction  other than the State of New Jersey.  Each party hereto
hereby irrevocably consents, for itself and its legal representatives, partners,
successors and assigns, to the exclusive jurisdiction of the Courts of the State
of New Jersey for all purposes in connection  with any action or proceeding that
arises from or relates to this

                                       7
<PAGE>

Agreement,  and further  agrees that,  subject to Section 8, any action  arising
from or relating to this Agreement  shall be instituted  and prosecuted  only in
the courts of the State of New Jersey,  and hereby waives any rights it may have
to  personal  service of  summons,  complaint,  or other  process in  connection
therewith,  and agrees that service may be made by registered or certified  mail
to such party at the address set forth in Section 11.4.

      11.6 Headings. The section headings in this Agreement are inserted only as
a matter of convenience, and in no way define, limit, or extend or interpret the
scope of this Agreement or of any particular section.

      11.7 Severability.  In case any one or more of the provisions contained in
this  Agreement  shall,  for  any  reason,  be held to be  invalid,  illegal  or
unenforceable in any respect,  such invalidity,  illegality or  unenforceability
shall not affect any other  provisions  of this  Agreement,  and this  Agreement
shall be construed as if such invalid,  illegal or  unenforceable  provision had
never been contained in this  Agreement.  To the extent  permitted by applicable
law,  the  parties  hereby  waive any  provision  of law that  would  render any
provision of this Agreement prohibited or unenforceable in any respect.

      11.8  Counterparts.  This  Agreement  may  be  executed  in  two  or  more
counterparts,  each of  which  shall be  deemed  an  original,  but all of which
together shall constitute one and the same instrument.

      11.9 Legal Counsel.  Legal Counsel.  The parties  hereto  acknowledge  and
agree that RIKER, DANZIG,  SCHERER, HYLAND & PERRETTI LLP ("Riker") has acted as
counsel  to the  LICENSEE  and may  continue  to do so in the sole and  absolute
discretion of the LICENSEE and Riker. The parties further  acknowledge and agree
that Riker is acting as counsel to the LICENSEE with respect to the transactions
contemplated  by this  Agreement  and that the  OWNER has been  advised  to seek
independent legal counsel and has availed himself of this right, or waived their
right to so. The OWNER  specifically  waives any conflicts of interest which may
arise in connection  with Riker's  representation  of the LICENSEE in connection
with the negotiation and consummation of the  transactions  contemplated by this
Agreement.

      11.10 Third-Party Benefits.  None of the provisions of this Agreement will
be for the benefit of, or enforceable by, any third-party beneficiary.

      11.11  Agreement   Negotiated.   Each  party   acknowledges   that  it  is
sophisticated  and has consulted legal counsel with respect to this transaction.
As a  consequence,  the  parties  do not  believe  that the  presumption  of any
statutory or common law rule relating to the interpretation of contracts against
the  drafter  of any  particular  clause  should  be  applied  in this  case and
therefore waive its effects.

                                       8
<PAGE>

      IN WITNESS  WHEREOF,  the parties  hereto have caused this Agreement to be
duly executed, as of the day and year first above written.

WITNESS:                                    OWNER:

------------------------            ----------------------------
                                    JOSE ANTONIO O'DALY

                                    LICENSEE:
                                    ASTRALIS, LLC

                                    By:
------------------------            ----------------------------
                                       Name: Mike Ajnsztajn
                                       Title:  Manager

                                    By:
------------------------            ----------------------------
                                       Name: Jose Antonio O'Daly
                                       Title: Manager

                                       9ASSIGNMENT OF LICENSE

      THIS ASSIGNMENT OF LICENSE (this "Assignment") is made as of the 13th day
of November, 2001 by and between ASTRALIS, LLC., a New Jersey limited liability
company ("Assignor") and HERCULES DEVELOPMENT GROUP, INC., a Colorado
corporation ("Assignee").

      WHEREAS, JOSE ANTONIO O'DALY ("Owner") and Assignor are party to a certain
License Agreement dated April 26, 2001, attached hereto as Exhibit A (the
"License Agreement');

      WHEREAS, pursuant to the License Agreement, Owner granted Assignor an
exclusive license to use and exploit certain inventions and technology for the
treatment and clinical remission of psoriasis;

      WHEREAS, Assignor wishes to assign, and Assignee wishes to acquire all of
Assignor's rights and obligations under the Agreement; and

      WHEREAS, prior to the date of this Assignment, Assignee has notified
Assignor in writing of its intention to be bound by all of the terms and
conditions of the License Agreement.

      NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, Assignor hereby assigns and
transfers to Assignee all of its rights and obligations under the License
Agreement and Assignee hereby agrees to be bound by all of the terms and
conditions of the License Agreement.

      This Assignment may be executed in counterparts each of which shall be an
original document.

<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be
executed as of the date set forth above.

                                                ASTRALIS, L.L.C.

                                                By: ___________________________
                                                      Name: Mike Ajnsztajn
                                                      Title: Managing Member

                                                HERCULES DEVELOPMENT GROUP,
                                                INC.

                                                By: ___________________________
                                                      Name: Shai Stern
                                                      Title: President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]